Verona Pharma Plc Share Price London S.E.
Equities
GB00B06GSH43
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
05-13 | HC Wainwright Adjusts Price Target on Verona Pharma to $30 From $32, Maintains Buy Rating | MT |
05-09 | Verona Pharma Signs Financing Agreements for Up to $650 Million | MT |
Sales 2024 * | 5.3M 6.73M 530M | Sales 2025 * | 75.71M 96.16M 7.57B | Capitalization | 829M 1.05B 82.86B |
---|---|---|---|---|---|
Net income 2024 * | -104M -132M -10.4B | Net income 2025 * | -65M -82.55M -6.5B | EV / Sales 2024 * | 122 x |
Net cash position 2024 * | 184M 234M 18.39B | Net cash position 2025 * | 146M 186M 14.64B | EV / Sales 2025 * | 9.01 x |
P/E ratio 2024 * |
-13.7
x | P/E ratio 2025 * |
-32.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
Latest transcript on Verona Pharma Plc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 31/01/20 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 29/02/20 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16/06/16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 11/09/16 |
David Ebsworth
CHM | Chairman | 69 | 30/11/14 |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |